Cure My Disease

Don't miss your cure!

 Log in / Sign up

Glaucoma implant tested for Office-Based eye care

NCT ID NCT07816692

Disease control Sponsor: Glaukos Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are observing whether a tiny implant that releases travoprost can be safely placed inside the eye during an office visit. The implant is designed to lower eye pressure in people with open angle glaucoma or ocular hypertension. The study follows 30 participants to see how well the procedure works outside a hospital operating room.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a travoprost-releasing implant placed inside the eye
What this could lead to
If it works, this could let people with glaucoma or high eye pressure receive a sustained-release implant in a regular office setting instead of a hospital operating room.
What could go wrong
This is a small observational study of 30 people, so it cannot prove the implant works better than standard care. Eye procedures carry risks of infection, inflammation, or implant-related problems.
Why investors are watching

Glaukos sells iDose TR, an implant that delivers travoprost inside the eye to lower pressure. This 30-person observational study checks how the implant performs when doctors place it in an office-based surgery setting rather than a hospital operating room. For a small company with this product as a key growth driver, evidence that the procedure works outside controlled trial conditions matters to how broadly doctors adopt it.

If it works: If the study shows the implant is administered safely in an office setting, Glaukos may gain support for wider use among eye doctors who prefer to treat patients in their own clinics.

If it fails: Observational studies of this size can miss rare safety problems, and any sign of harm or difficulty with office-based placement may slow adoption. Clinical programs often produce disappointing results.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults 18 years of age or older with open-angle glaucoma or ocular hypertension

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT) Exclusion Criteria: * Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye Active ocular infection or inflammation History of hypersensitivity to travoprost or implant components Recent ocular surgery Uncontrolled systemic disease Any condition preventing safe implantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ocular hypertension (OHT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma ocular hypertension open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ocular hypertension (OHT) Open-angle glaucoma (OAG)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Glaukos Investigative Site

    RECRUITING

    Austin, Texas, 78746, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.